New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
05:53 EDTAZN, BBRYStocks with implied volatility movement; AZN BBRY
Stocks with implied volatility movement; AstraZeneca (AZN) 44, BlackBerry (BBRY) 53 according to iVolatility.
News For AZN;BBRY From The Last 14 Days
Check below for free stories on AZN;BBRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 31, 2014
09:04 EDTBBRYBlackBerry downplays loss of Ford business to Apple, WSJ says
Subscribe for More Information
06:24 EDTAZNAstraZeneca offers 'no comment' on Pfizer, Reuters reports
Subscribe for More Information
July 30, 2014
11:57 EDTBBRYNew COO Beard says BlackBerry will 'prove' people incorrect, WSJ says
Even though BlackBerry (BBRY) is up against obstacles from rivals such as Apple (AAPL) and Google's (GOOG) Android smartphones, the company's new COO Marty Beard says that the firm is positioned to "prove people wrong" and take advantage of an emerging market for internet-connected devices, according to The Wall Street Journal, citing comments from Beard. Reference Link
06:10 EDTAZNAstraZeneca enters respiratory disease transaction with Almirall
AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875M on completion, and up to $1.22B in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments. Upon completion of the transaction, AstraZeneca will own the rights for the development and commercialization of Almirall’s existing proprietary respiratory business, including rights to revenues from Almirall’s existing partnerships, as well as its pipeline of investigational novel therapies. The franchise includes Eklira, LAS40464, LAS100977 or abediterol, and multiple pre-clinical programs. Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, will also transfer to AstraZeneca. Almirall’s pipeline of respiratory assets and its device capabilities further strengthen AstraZeneca’s respiratory portfolio, which includes Symbicort and Pulmicort, as well as the company’s investigational medicines in development. The addition of aclidinium and the combination of aclidinium with formoterol, both in proprietary Genuair device, will allow AstraZeneca to offer patients a choice between dry powder inhaler and metered dose inhaler devices across a range of molecules and combinations. AstraZeneca and Almirall anticipate that, subject to local consultation and legislation, a significant number of employees dedicated to the respiratory business, including Almirall Sofotec employees, will transfer to AstraZeneca. The transaction is subject to certain competition law clearances as well as other customary terms and conditions. The companies anticipate the transaction will complete by the end of 2014.Reference Link
July 29, 2014
12:39 EDTBBRYFord replacing employees' BlackBerry phones with iPhones, Bloomberg reports
Subscribe for More Information
12:05 EDTBBRYStocks with call strike movement; BBRY TWTR
BlackBerry (BBRY) December 11 call option implied volatility decreased 7% to 53, Twitter (TWTR) November 44 call option implied volatility decreased 2% to 54 according to IVolatility.
09:02 EDTBBRYBlackBerry acquires Secusmart
BlackBerry has entered into an agreement to acquire Secusmart GmbH. The transaction is subject to the satisfaction of certain customary conditions, including the receipt of regulatory approvals.
08:53 EDTBBRYBlackBerry estimates raised after management meeting at Wells Fargo
Wells Fargo raised its estimates for BlackBerry to reflect higher hardware selling prices after meeting with management. The firm raised its FY15 estimate to (58c) from (88c) and FY16 estimate to (27c) from (82c). Wells also upped its price target range for shares to $9.50-$10.50 from $8.50-$9.50 while keeping a Market Perform rating on the stock. It adds that based on its talks with management, BlackBerry has several levers to drive cash flow.
July 28, 2014
09:25 EDTBBRYBlackBerry CEO says no buyout offers on table amid revamp, Bloomberg says
Subscribe for More Information
07:21 EDTBBRYBlackBerry, Dell play-down risk of Apple-IBM partnership, Reuters says
Subscribe for More Information
05:36 EDTAZNQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 25, 2014
16:49 EDTBBRYS&P ends week little changed amid earnings deluge
The S&P 500 finished little changed this week as mixed U.S. economic data and continued geopolitical uncertainty offset strong earnings from a number of major companies and upbeat overseas economic data. MACRO NEWS: U.S. economic data was mixed, as fewer than expected jobless claims were reported and durable goods orders for June were slightly higher than expected, but new home sales for June and a preliminary purchasing managers' index for July came in below expectations... Investors received some positive economic news from overseas, as HSBC's preliminary China purchasing managers' index for July reached an 18-month high. Meanwhile, a preliminary PMI for the euro zone for July came in at 54, versus 52.8 in June... Ongoing conflicts between Israel and Hamas and Russia and Ukraine kept investors on edge, with Friday reports indicating that no truce accord had been reached in Israel and that Russia was building up its troop presence along the Ukrainian border. COMPANY NEWS: Among the notable companies whose stocks rose after they reported quarterly results were Facebook (FB), Apple (AAPL), Allergan (AGN) and Chipotle Mexican Grill (CMG). Notable companies whose stocks sold off following their results included Netflix (NFLX), Harley-Davidson (HOG), General Motors (GM), Boeing (BA), McDonald's (MCD) and Pandora (P)... McDonald's was also hit this week by revelations that its restaurants in China had sold expired meat that was allegedly intentionally supplied by a China-based company. Yum! Brands (YUM) and a provider of products to Starbucks (SBUX) are also believed to have bought and sold expired meat from the supplier... In M&A news, Bloomberg reported that real estate website operator Zillow (Z) held talks about buying its rival, Trulia (TRLA). Both stocks surged. Shares of SodaStream (SODA) also rallied after Bloomberg reported that the company is in talks about selling itself to an investment firm that would take the beverage system maker private... On Monday, hedge fund manager Bill Ackman promised on CNBC that his presentation about Herbalife (HLF) would show why the company "is going to collapse." But the shares actually surged higher during and immediately after Ackman's presentation. Ackman has a large short position in the stock and notably alleged it is a pyramid scheme... BlackBerry's (BBRY) CEO told the Financial Times that his company was in early talks about partnering with companies to target the enterprise markets, in order to counter a recently announced partnership between Apple and IBM (IBM). INDEXES: For the week, the Dow fell 0.83% to 16,960.57, the Nasdaq rose 0.4% to 4,449.56, and the S&P was flat at 1,978.34.
July 24, 2014
10:37 EDTBBRYBlackBerry CEO says in enterprise partnership talks, FT reports
Subscribe for More Information
10:15 EDTBBRYBlackBerry calls active on renewed takeover speculation
Blackberry July weekly 10 and 10.5 calls are active on total call volume of 27K contracts (2K puts) on renewed takeover speculation. July weekly call option implied volatility is at 70, August is at 50, September is at 49, October is at 51; compared to its 26-week average of 52 according to Track Data. Active call volume suggests traders taking positions for large near term price movement
09:58 EDTBBRYBlackBerry spikes higher, levels to watch
Subscribe for More Information
09:46 EDTBBRYRumor: BlackBerry moves up on renewed takeover chatter
Subscribe for More Information
July 23, 2014
11:55 EDTBBRYStocks with call strike movement; BBRY TWTR
Subscribe for More Information
July 22, 2014
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
12:05 EDTBBRYStocks with call strike movement; BBRY TWTR
Subscribe for More Information
07:31 EDTBBRYBlackBerry appoints Marty Beard as COO
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use